Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Procainamide-induced hemolytic anemia.

G W Jones, T L George, R D Bradley

    Transfusion
    |March 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Procainamide hydrochloride treatment can cause hemolytic anemia, a condition where red blood cells are destroyed. This study details a case where stopping the drug reversed the anemia, highlighting a rare side effect.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    IL-27: a double agent in the IL-6 family.

    Clinical and experimental immunology·2018
    Same author

    Grasping with a soft glove: intrinsic impedance control in pneumatic actuators.

    Journal of the Royal Society, Interface·2017
    Same author

    The Medical Bookshelf.

    Postgraduate medicine·2016
    Same author

    A successful clinical pilot registry of four radiation oncology practices in Africa and Ontario.

    The Central African journal of medicine·2014
    Same author

    Heterotrophic bacteria of the freshwater neuston and their ability to act as plasmid recipients under nutrient deprived conditions.

    Microbial ecology·2013
    Same author

    Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A.

    Annals of the rheumatic diseases·2013
    Same journal

    Investigation of the preanalytical stability of blood donor samples.

    Transfusion·2026
    Same journal

    The need for dried plasma-Still a national issue: Where are we and recommendations.

    Transfusion·2026
    Same journal

    Spray dried plasma manufactured from apheresis and whole blood derived plasma.

    Transfusion·2026
    Same journal

    Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

    Transfusion·2026
    Same journal

    AABB survey on directed blood donation practices.

    Transfusion·2026
    Same journal

    Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

    Transfusion·2026
    See all related articles

    Area of Science:

    • Hematology
    • Clinical Pharmacology

    Background:

    • Procainamide hydrochloride is a medication used to treat cardiac arrhythmias.
    • Drug-induced hemolytic anemia is a known, though uncommon, adverse effect of certain medications.
    • Drug-induced lupus erythematosus is a frequently reported sequela of procainamide therapy.

    Observation:

    • A patient developed hemolytic anemia during 11 months of procainamide hydrochloride treatment.
    • Hemoglobin levels decreased during treatment and increased significantly after drug cessation.
    • The patient did not present with symptoms of drug-induced lupus erythematosus.

    Findings:

    • Direct antiglobulin tests were consistently positive, indicating antibody-mediated red blood cell destruction.
    • An antibody eluate from the patient's red blood cells showed panagglutinability.

    Related Experiment Videos

  • The identified antibody reacted with specific red blood cell antigens (Rhnull, D--, LW negative, U negative) independently of procainamide.

    • Implications:

    • This case highlights procainamide hydrochloride as a potential cause of hemolytic anemia.
    • The antibody characteristics are similar to those seen with alpha-methyl-dopa-induced antibodies.
    • Further research may clarify the immunogenetic mechanisms underlying procainamide-induced hemolytic anemia.